Actively Recruiting
Efficacy of Metoclopramide in Poor Ovarian Response IVF Patients
Led by Barzilai Medical Center · Updated on 2025-02-10
60
Participants Needed
1
Research Sites
373 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Poor ovarian response population of ART are considered the biggest challenge for providers. Hitherto, no one protocol has been proven to be effect in this subgroup of IVF patients. Metoclopramide belongs to the antiemetic group, used for motion sickness and during early gestation for hyperemesis gravidarum. The mechanism of action is antagonisim to dopamine receptors. We hypothesize than by blocking dopamine receptors and decreasing the dopaminergic tone there is a possibility to increase the sensitivity of ovarian response to gonadotropins during controlled ovarian stimulation and result in increased oocyte retrival.
CONDITIONS
Official Title
Efficacy of Metoclopramide in Poor Ovarian Response IVF Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Women with poor ovarian response according to the Bologna criteria
You will not qualify if you...
- Allergy to metoclopramide
- Prolactinemia
- Women treated with dopamine agonists
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Barzilai University Medical Center
Ashkelon, Ashkelon District, Israel, 7830604
Actively Recruiting
Research Team
L
Leon Grin, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here